Abstract
The hedgehog pathway inhibitor vismodegib provides a
new treatment option for metastasized and locally advanced
basal cell carcinoma for which surgical excision or
radiotherapy is contraindicated. However, adverse events
frequently lead to discontinuation of therapy and development
of tumor resistance is quite common. In the
future, combination therapy could reduce the occurrence
of tumor resistance.
new treatment option for metastasized and locally advanced
basal cell carcinoma for which surgical excision or
radiotherapy is contraindicated. However, adverse events
frequently lead to discontinuation of therapy and development
of tumor resistance is quite common. In the
future, combination therapy could reduce the occurrence
of tumor resistance.
| Original language | Dutch |
|---|---|
| Pages (from-to) | 550-552 |
| Number of pages | 3 |
| Journal | Nederlands Tijdschrift voor Dermatologie en Venereologie |
| Volume | 27 |
| Issue number | 10 |
| Publication status | Published - Oct 2017 |